Tarver took the position in late July after the announcement that CDRH’s director of the past 15 years, Jeff Shuren, M.D., ...

Industry leaders explored the risks and benefits of adopting a China Plus One strategy at Advamed’s The MedTech Conference in ...

The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem that regulators and industry need to work on together.

As medtech companies, experts and regulators gather in Toronto, FDA leadership changes and the upcoming U.S. presidential ...

Recommended Reading FDA finalizes Voluntary Malfunction Summary Reporting guidance Advamed has voiced support for the Food and Drug Administration’s plans to update guidance on addressing ...

Canada’s device agency plans to issue guidance on machine learning, and the FDA plans to release a draft guidance next year on lifecycle management and premarket submissions for AI devices.

*Based on data released by the Federal Election Commission on October 08, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

As a member of the Executive Committee of the AdvaMed Board of Directors, he contributes to strategic initiatives that advance the medical technology sector. He also serves on the AdvaMedDx Board ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...